MYCN and neuroblastoma: Notably, the lasting antitumor effects and long-term survival were achieved in this model of recurrent, multidrug-resistant NB integrating several high-risk features (MYCN amplification and an acquired loss of p53 function) with low drug doses administered once a week and causing no adverse effects during and after the treatment period.